Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2018
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung AdenocarcinomaPo-Hao Feng, Kuan-Yuan Chen, Yu-Chen Huang, et al.
Journal of Medicinal Chemistry|October 4, 2021
Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor ModelKun-Hung Lee, Wan-Ching Yen, Wen-Hsing Lin, et al.
Molecular Cancer|September 20, 2014
OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathwayYa-Ching Lu, Joseph T Chang, Chun-Ta Liao, et al.
Biochemical Pharmacology|May 15, 2009
Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitorJia-Jing Wu, Hung-Kuan Tang, Teng-Kuang Yeh, et al.
Translational Oncology|October 17, 2020
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapyYun-Yu Chen, Chen-Fu Lo, Tai-Yu Chiu, et al.
European Journal of Medicinal Chemistry|September 9, 2022
Benzo[b]thiophene-2-carboxamides as novel opioid receptor agonists with potent analgesic effect and reduced constipationRamajayam Kuppusamy, Ying-Ting Hsu, Yi-Yu Ke, et al.
Frontiers in Immunology|July 22, 2022
Increased Interleukin-17 and Glucocorticoid Receptor-β Expression in Interstitial Lung Diseases and Corticosteroid InsensitivityChun-Yu Lo, Chun-Hua Wang, Chih-Wei Wang, et al.
Anticancer Research|August 5, 2010
Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075Ching-Ping Chen, Chih-Bo Hu, Kai-Chia Yeh, et al.
Journal of Medicinal Chemistry|June 24, 2024
Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune MicroenvironmentMu-Chun Li, You-Liang Lai, Po-Hsien Kuo, et al.
Journal of Medicinal Chemistry|February 7, 2023
Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung CancerMu-Chun Li, Mohane Selvaraj Coumar, Shu-Yu Lin, et al.
Pageof 21